Researchers published Phase I first-in-human data for rezatapopt in the New England Journal of Medicine showing objective responses in heavily pretreated patients whose tumors harbor the TP53 Y220C mutation. PMV Pharmaceuticals reported the drug was generally well tolerated across dose‑escalation cohorts (77 patients) and provided biomarker evidence consistent with selective binding to the Y220C pocket and restoration of wild‑type p53 function. The study establishes proof‑of‑concept for mutant‑p53 reactivation across multiple solid tumor types and supports PMV’s planned registrational Phase II path and an intended NDA filing in platinum‑resistant/refractory ovarian cancer in Q1 2027.